FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019925885> ?p ?o ?g. }

• W2019925885 endingPage "109" @default.
• W2019925885 startingPage "100" @default.
• W2019925885 abstract "Background Two arms with FOLFIRI, with or without cetuximab, were initially included in the randomized phase III intergroup clinical trial NCCTG (North Central Cancer Treatment Group) N0147. When other contemporary trials demonstrated no benefit to using irinotecan as adjuvant therapy, the FOLFIRI-containing arms were discontinued. We report the clinical outcomes for patients randomized to FOLFIRI with or without cetuximab. Patients and Methods After resection, patients were randomized to 12 biweekly cycles of FOLFIRI, with or without cetuximab. KRAS (Kirsten rat sarcoma viral oncogene homolog) mutation status was retrospectively determined in a central lab. The primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS) and toxicity. Results One hundred and six patients received FOLFIRI and 40 received FOLFIRI plus cetuximab. Median follow-up was 5.95 years (range, 0.1-7.0 years). The addition of cetuximab showed a trend toward improved DFS (hazard ratio [HR], 0.53; 95% CI, 0.26-1.1; P = .09) and OS (HR, 0.45; 95% CI, 0.17-1.16; P = .10) in the overall group, regardless of KRAS status, and in patients with wild type KRAS. Grade ≥ 3 nonhematologic adverse effects were significantly increased in the cetuximab versus FOLFIRI-alone arm (68% vs. 46%; P = .02). Adjuvant FOLFIRI resulted in a 3-year DFS less than that expected for FOLFOX. Conclusion In this small randomized subset of patients with resected stage III colon cancer, the addition of cetuximab to FOLFIRI was associated with a nonsignificant trend toward improved DFS and OS. Nevertheless, considering the limitations of this analysis, FOLFOX without the addition of a biologic agent remains the standard of care for adjuvant therapy in resected stage III colon cancer." @default.
• W2019925885 created "2016-06-24" @default.
• W2019925885 creator A5003724529 @default.
• W2019925885 creator A5004280495 @default.
• W2019925885 creator A5019214686 @default.
• W2019925885 creator A5022512837 @default.
• W2019925885 creator A5027623921 @default.
• W2019925885 creator A5033379126 @default.
• W2019925885 creator A5034306031 @default.
• W2019925885 creator A5045618241 @default.
• W2019925885 creator A5049580044 @default.
• W2019925885 creator A5053082993 @default.
• W2019925885 creator A5055583536 @default.
• W2019925885 creator A5057458005 @default.
• W2019925885 creator A5060306466 @default.
• W2019925885 creator A5061822229 @default.
• W2019925885 creator A5069073626 @default.
• W2019925885 creator A5069117871 @default.
• W2019925885 creator A5070331492 @default.
• W2019925885 creator A5072203753 @default.
• W2019925885 creator A5078890913 @default.
• W2019925885 creator A5088841234 @default.
• W2019925885 creator A5090473173 @default.
• W2019925885 date "2014-06-01" @default.
• W2019925885 modified "2023-10-03" @default.
• W2019925885 title "Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147" @default.
• W2019925885 cites W1974365898 @default.
• W2019925885 cites W2000366267 @default.
• W2019925885 cites W2037339308 @default.
• W2019925885 cites W2061677297 @default.
• W2019925885 cites W2095201384 @default.
• W2019925885 cites W2121113526 @default.
• W2019925885 cites W2131413118 @default.
• W2019925885 cites W2132352600 @default.
• W2019925885 cites W2134142320 @default.
• W2019925885 cites W2141801755 @default.
• W2019925885 cites W2144425748 @default.
• W2019925885 cites W2159342260 @default.
• W2019925885 cites W2409420104 @default.
• W2019925885 cites W4246905873 @default.
• W2019925885 cites W4293241248 @default.
• W2019925885 cites W4385789423 @default.
• W2019925885 doi "https://doi.org/10.1016/j.clcc.2013.12.002" @default.
• W2019925885 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4019685" @default.
• W2019925885 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24512953" @default.
• W2019925885 hasPublicationYear "2014" @default.
• W2019925885 type Work @default.
• W2019925885 sameAs 2019925885 @default.
• W2019925885 citedByCount "39" @default.
• W2019925885 countsByYear W20199258852012 @default.
• W2019925885 countsByYear W20199258852014 @default.
• W2019925885 countsByYear W20199258852015 @default.
• W2019925885 countsByYear W20199258852016 @default.
• W2019925885 countsByYear W20199258852017 @default.
• W2019925885 countsByYear W20199258852018 @default.
• W2019925885 countsByYear W20199258852019 @default.
• W2019925885 countsByYear W20199258852020 @default.
• W2019925885 countsByYear W20199258852021 @default.
• W2019925885 countsByYear W20199258852022 @default.
• W2019925885 crossrefType "journal-article" @default.
• W2019925885 hasAuthorship W2019925885A5003724529 @default.
• W2019925885 hasAuthorship W2019925885A5004280495 @default.
• W2019925885 hasAuthorship W2019925885A5019214686 @default.
• W2019925885 hasAuthorship W2019925885A5022512837 @default.
• W2019925885 hasAuthorship W2019925885A5027623921 @default.
• W2019925885 hasAuthorship W2019925885A5033379126 @default.
• W2019925885 hasAuthorship W2019925885A5034306031 @default.
• W2019925885 hasAuthorship W2019925885A5045618241 @default.
• W2019925885 hasAuthorship W2019925885A5049580044 @default.
• W2019925885 hasAuthorship W2019925885A5053082993 @default.
• W2019925885 hasAuthorship W2019925885A5055583536 @default.
• W2019925885 hasAuthorship W2019925885A5057458005 @default.
• W2019925885 hasAuthorship W2019925885A5060306466 @default.
• W2019925885 hasAuthorship W2019925885A5061822229 @default.
• W2019925885 hasAuthorship W2019925885A5069073626 @default.
• W2019925885 hasAuthorship W2019925885A5069117871 @default.
• W2019925885 hasAuthorship W2019925885A5070331492 @default.
• W2019925885 hasAuthorship W2019925885A5072203753 @default.
• W2019925885 hasAuthorship W2019925885A5078890913 @default.
• W2019925885 hasAuthorship W2019925885A5088841234 @default.
• W2019925885 hasAuthorship W2019925885A5090473173 @default.
• W2019925885 hasBestOaLocation W20199258852 @default.
• W2019925885 hasConcept C121608353 @default.
• W2019925885 hasConcept C126322002 @default.
• W2019925885 hasConcept C141071460 @default.
• W2019925885 hasConcept C143998085 @default.
• W2019925885 hasConcept C168563851 @default.
• W2019925885 hasConcept C203092338 @default.
• W2019925885 hasConcept C207103383 @default.
• W2019925885 hasConcept C2776705615 @default.
• W2019925885 hasConcept C2778260052 @default.
• W2019925885 hasConcept C2779998722 @default.
• W2019925885 hasConcept C2780259306 @default.
• W2019925885 hasConcept C2780962732 @default.
• W2019925885 hasConcept C2781187634 @default.
• W2019925885 hasConcept C44249647 @default.
• W2019925885 hasConcept C526805850 @default.
• W2019925885 hasConcept C71924100 @default.

• next